<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488900</url>
  </required_header>
  <id_info>
    <org_study_id>A104-01DL2001</org_study_id>
    <nct_id>NCT04488900</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects</brief_title>
  <official_title>Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) and Single and Multiple Ascending Oral Dose Administration in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human (FIH), randomized, placebo-controlled, 3-part, single
      ascending dose (SAD) and multiple ascending dose (MAD) study. The study is designed to assess
      the safety, tolerability, PK, and PD of orally administered CKD-508 capsules in healthy
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 26, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>28 days post dose</time_frame>
    <description>The relationship of each adverse event to the investigational product was assessed by the investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma CKD-508 concentrations after dosing</measure>
    <time_frame>28 days post dose</time_frame>
    <description>Peak plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum plasma CKD-508 concentrations after dosing</measure>
    <time_frame>28 days post dose</time_frame>
    <description>Time of peak plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in plasma CKD-508 concentrations in time after dosing</measure>
    <time_frame>28 days post dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in LDL-c</measure>
    <time_frame>28 days post dose</time_frame>
    <description>Pharmacodynamics endpoint</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>CKD-508 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose administration of CKD-508</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CKD-508 multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose administration of CKD-508</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-508 single dose</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>CKD-508 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-508 multiple dose</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>CKD-508 multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject voluntarily agrees to participate in this study and signs an Independent
             Ethics Committee (IEC)-approved informed consent prior to performing any of the
             Screening Visit procedures.

          -  Males and females between 18 to 55 years of age, inclusive, at the Screening Visit.

          -  Females of non-childbearing potential (surgically sterile [hysterectomy or
             oophorectomy] or postmenopausal (amenorrhea for more than 12 months with
             follicle-stimulating hormone (FSH) in postmenopausal range confirmed by an FSH test).

          -  Males must be unable to procreate (defined as surgically sterile [i.e., had a
             vasectomy â‰¥6 months prior to screening]) or must agree to use highly effective form of
             birth control from screening through 90 days after study completion.

          -  Non-smokers (or other nicotine use) as determined by history (no nicotine use over the
             past 6 months).

        Exclusion Criteria:

          -  Subject has clinically significant history or evidence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, neurological, immunological or
             psychiatric disorder(s) as determined by the PI or designee.

          -  Subject has any disorder that would interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          -  Subject has any concurrent disease or condition that, in the opinion of the PI, would
             make the subject unsuitable for participation in the clinical study.

          -  Subject has history of alcohol and/or illicit drug abuse within 2 years of Screening
             Visit.

          -  Subject has positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C
             antibody or human immunodeficiency virus (HIV) antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muna Albayaty, M.D</last_name>
    <phone>+44 (0)1895614592</phone>
    <email>Albayaty@parexel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Early Phase Clinical Unit</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muna Albayaty,, M.D</last_name>
      <phone>+44 (0)1895614592</phone>
      <email>Albayaty@parexel.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2020</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

